Edwards Lifesciences (EW) Accumulated Expenses (2009 - 2026)

Edwards Lifesciences' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 0.6% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 0.6% YoY), while the FY2025 annual figure was $1.6 billion, up 21.78% from the prior year.
• Accumulated Expenses was $1.2 billion for Q1 2026 at Edwards Lifesciences, down from $1.6 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 billion in Q3 2024 to a low of $739.5 million in Q3 2022.
• Historically, Accumulated Expenses has averaged $1.1 billion across 5 years, with a median of $939.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 70.44% in 2024, then decreased 20.13% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $795.0 million in 2022, then grew by 7.72% to $856.4 million in 2023, then surged by 49.74% to $1.3 billion in 2024, then grew by 21.78% to $1.6 billion in 2025, then decreased by 22.93% to $1.2 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.2 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.